SYNLAB AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.42 EUR | -0.38% |
|
+1.36% | -8.68% |
| 04-22 | Synlab Faces Cyber Attack in Italy | MT |
| 04-21 | Dpa-AFX Overview: COMPANIES - The most important news from the weekend | DP |
| Sales 2024 * | 2.91B 3.12B 4.26B | Sales 2025 * | 3.1B 3.32B 4.53B | Capitalization | 2.31B 2.47B 3.37B |
|---|---|---|---|---|---|
| Net income 2024 * | 91M 97.3M 133M | Net income 2025 * | 69M 73.78M 101M | EV / Sales 2024 * | 1.33 x |
| Net Debt 2024 * | 1.57B 1.68B 2.3B | Net Debt 2025 * | 1.61B 1.72B 2.35B | EV / Sales 2025 * | 1.26 x |
| P/E ratio 2024 * |
25.6
x | P/E ratio 2025 * |
33.9
x | Employees | 23,538 |
| Yield 2024 * |
0.86% | Yield 2025 * |
2.1% | Free-Float | 14.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on SYNLAB AG
More press releases
| 1 day | -0.38% | ||
| 1 week | +1.36% | ||
| Current month | -3.96% | ||
| 1 month | -0.86% | ||
| 3 months | -11.54% | ||
| 6 months | +4.62% | ||
| Current year | -8.68% |
1 week
10.42
10.50
1 month
10.0010.96
Current year
10.0012.30
1 year
8.0212.30
3 years
6.6924.60
5 years
6.6924.60
10 years
6.6924.60
| Managers | Title | Age | Since |
|---|---|---|---|
Mathieu Floreani
CEO | Chief Executive Officer | 56 | 21-01-25 |
Sami Badarani
DFI | Director of Finance/CFO | 61 | 21-01-25 |
Henrik Andreasen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Ebsworth
CHM | Chairman | 69 | 21-01-10 |
| Founder | 63 | 97-12-31 | |
Peter Catterall
BRD | Director/Board Member | 55 | 21-01-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 10.42 | -0.38% | 2,853 |
| 24-04-25 | 10.46 | -0.38% | 150 |
| 24-04-24 | 10.5 | +0.19% | 0 |
| 24-04-23 | 10.48 | 0.00% | 0 |
| 24-04-22 | 10.48 | +1.95% | 0 |
Delayed Quote Deutsche Boerse AG, April 26, 2024 at 09:59 am
More quotes
Synlab AG is a Germany based clinical laboratory and medical diagnostic services provider. The Company is engaged in laboratory services for human and veterinary medicine, as well as environmental analysis.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
10.5
EUR
Average target price
14.5
EUR
Spread / Average Target
+38.10%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -15.34% | 1.03B |
- Stock Market
- Equities
- SYAB Stock
- SYAB Stock
